Cancer stem cells and differentiation therapy

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Xiong JinHyunggee Kim

Abstract

Cancer stem cells can generate tumors from only a small number of cells, whereas differentiated cancer cells cannot. The prominent feature of cancer stem cells is its ability to self-renew and differentiate into multiple types of cancer cells. Cancer stem cells have several distinct tumorigenic abilities, including stem cell signal transduction, tumorigenicity, metastasis, and resistance to anticancer drugs, which are regulated by genetic or epigenetic changes. Like normal adult stem cells involved in various developmental processes and tissue homeostasis, cancer stem cells maintain their self-renewal capacity by activating multiple stem cell signaling pathways and inhibiting differentiation signaling pathways during cancer initiation and progression. Recently, many studies have focused on targeting cancer stem cells to eradicate malignancies by regulating stem cell signaling pathways, and products of some of these strategies are in preclinical and clinical trials. In this review, we describe the crucial features of cancer stem cells related to tumor relapse and drug resistance, as well as the new therapeutic strategy to target cancer stem cells named "differentiation therapy."

References

Sep 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·M IlyasW F Bodmer
Feb 3, 2000·Proceedings of the National Academy of Sciences of the United States of America·T T HuangS Miyamoto
Nov 2, 2001·Nature·T ReyaI L Weissman
Jan 24, 2002·Nature·Pierre GermainHinrich Gronemeyer
Jun 18, 2002·Nature Genetics·Michael D TaylorDavid Hogg
Jul 9, 2002·Current Opinion in Genetics & Development·David M Panchision, Ronald D G McKay
Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Mar 17, 2004·Cancer Control : Journal of the Moffitt Cancer Center·Monica L Guzman, Craig T Jordan
Jan 5, 2005·Nature Reviews. Immunology·Frank J T Staal, Hans C Clevers
Jan 20, 2005·The British Journal of Dermatology·J ReifenbergerG Reifenberger
Apr 15, 2005·Nature·Tannishtha Reya, Hans Clevers
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Jul 22, 2005·Drug News & Perspectives·D HebenstreitA Duschl
Feb 3, 2006·Cancer Research·Spyros StylianouKeith Brennan
Jul 18, 2006·Cancer Cell·Denise K WaltersBrian J Druker
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick
Sep 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Julie B SneddonPatrick O Brown
Dec 2, 2006·Nature Reviews. Drug Discovery·Lee L Rubin, Frederic J de Sauvage
Dec 5, 2006·Oncogene·S Segditsas, I Tomlinson
Feb 3, 2007·The New England Journal of Medicine·Linda M ScottAnthony R Green
Feb 7, 2007·Cancer Research·Chenwei LiDiane M Simeone
May 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Matthias LauthRune Toftgård
Jun 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Piero DalerbaMichael F Clarke
Nov 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Anuradha PradhanGary W Reuther
Dec 1, 2007·Cell Death and Differentiation·A EramoR De Maria
Jan 19, 2008·Nature·Tobias SchattonMarkus H Frank
Feb 5, 2008·Cancer Cell·Zhen Fan YangSheung Tat Fan
Feb 13, 2008·Cell·Matthew S Hayden, Sankar Ghosh

❮ Previous
Next ❯

Citations

Apr 16, 2019·Journal of Neuroscience Research·Myrna A R Dent, Armando Aranda-Anzaldo
May 16, 2019·American Journal of Physiology. Cell Physiology·Stefania BrunoGiovanni Camussi
Oct 5, 2018·BMC Veterinary Research·Keisuke AoshimaTakashi Kimura
Oct 28, 2018·Expert Opinion on Therapeutic Targets·Laura HüserJochen Utikal
Sep 24, 2018·Cell and Tissue Research·Xiaoling GuoRenshan Ge
Mar 16, 2019·Experimental & Molecular Medicine·Chiara GaiGiovanni Camussi
Mar 21, 2018·Archives of Pharmacal Research·Md Saiful Islam Roney, Song-Kyu Park
May 16, 2019·Molecular Genetics & Genomic Medicine·Reihaneh Alsadat MahmoudianMohammad Mahdi Forghanifard
Jul 2, 2019·Journal of Nutritional Science and Vitaminology·Saki KanekoTomohiro Yano
Jan 12, 2021·Molecular Carcinogenesis·Naing L ShanNanjoo Suh
Feb 16, 2021·Frontiers in Pharmacology·Qinghui ZhengXuli Meng
May 25, 2021·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Beata BiesagaA Mucha-Małecka
May 28, 2021·Journal of Theoretical Biology·Tagari Samanta, Sandip Kar

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear translocation
ubiquitination

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

© 2022 Meta ULC. All rights reserved